Innovation made accessible for Ninewells Hospital Medical Microbiology with the cobas® 5800 system
Laboratories face competing pressures to streamline costs, add value, and drive growth while empowering employee productivity and enabling better patient decision-making. Those challenges are often complex, leading to trade-offs between flexibility, performance, efficiency, value, sustainability and success.
At Ninewells Hospital, we understand you are looking for your next chapter in innovative molecular testing complete with continuous access for samples, reagents and consumables. Together, we can help transform your testing and treatment.
Realise the future of molecular testing
The Molecular Work Area concept brings a shared approach to our family of molecular testing systems, with common reagents, a broad range of assays and uniform user interfaces.
We provide high-quality molecular diagnostics systems and assays to allow you to provide the best in testing within your laboratory.
The cobas ® 5800 system, a compact new addition to the portfolio, makes automation, consolidation, integration and standardisation more accessible than ever. The built-in scalability of the cobas ® 5800 system allows your laboratory to flexibly respond to changing needs, increasing value across the organisation while putting sustainability and success first.
Invest in innovation
We invest heavily in molecular diagnostics - new assays, instruments (systems), and enhancements through internal developments and external acquisitions. We stand behind every product and service and want to ensure the solution that you choose delivers a top-quality experience and fosters a long-term partnership.
?wid=402&fmt=png-alpha)
Optimising and ensuring the sustainability of your service
We understand that it isn't just about the equipment. Our healthcare consultants partner with you to optimise your workflow and processes with the right technology, IT and digital solutions to enable the best healthcare outcomes.
?wid=402&fmt=png-alpha)
FAQs
Frequently asked questions
The cobas® 5800 Systems – a scalable, cost-efficient solution for smaller labs seeking big lab performance or for bigger labs seeking small lab agility.
The need for reliable and timely results is met with our Molecular Work Area
By seamlessly integrating routine molecular testing in pressurised lab environments, the Molecular Work Area simplifies lab operations, getting patients on the path to effective treatment as soon as possible. Built for proactive growth and agile scaling, our Molecular Work Area meets the pressures of current healthcare environments while ensuring long-term sustainability by unlocking future possibilities in the advancements of medical diagnostics.
Roche healthcare consulting
Change can be a challenge, but it does not have to be. From process analysis and laboratory design to change management and data analysis, Roche Healthcare Consulting has the expertise your laboratory needs for an effective and streamlined transformation.
Our specialised and local experts can help you to optimise laboratory processes with the right solutions for your current and future needs. Our consultants will work with you to improve turnaround time (TAT), reduce errors, and create efficiencies while measuring performance criteria –financial, clinical, quality or personnel – every step of the way.
Molecular automation
Experience a new paradigm in workflow efficiency. We offer a range of standalone, physical, and virtual automation solutions that minimise laboratory inefficiency and maximise through cross-disciplinary connectivity. cobas® 5800 System can fully utilise the processing and sorting capabilities of our cobas® Prime and cobas® p 312/512/612 pre-analytical systems to streamline sample preparation and sorting.
When paired with cobas® infinity Laboratory Solution, the cobas® 5800 System can benefit from additional virtual workflow management as well.
Streamline your service
Get an integrated view of your laboratory ecosystem and remote control. With advanced IT automation, you can monitor your lab operations in real-time using navify® monitoring or manage remotely using navify® control.
Confidently meet key performance indicators and enhance your labs automation through web-based molecular insights dashboards through navify® analytics.
Service and support
Our team of national, regional and international application specialists are there when you need them, providing timely technical advice to help you get the most out of your tests and systems.
?scl=1&fmt=png-alpha&fit=crop,1)
FAQs
Frequently asked questions
The cobas® 5800 Systems – a scalable, cost-efficient solution for smaller labs seeking big lab performance or for bigger labs seeking small lab agility.
Improve the productivity of your floor space by running a broad menu of assays from a small footprint, using fully automated and standardised workflows. The cobas®5800 System offers a fully automated workflow encompassing sample supply, transfer and preparation, amplification and detection, result calculation and delivery to the LIS. All the technology required to automate each one of these steps is sitting neatly packed inside this single module, enabling a walkaway time of up to 4 hours when operating in continuous testing mode.
Big on features, small in footprint
Add capacity, improve capability, streamline confidence.
- 20–150 samples per day
- Broad menu of more than 25 assays*
- Up to 15 assays onboard at all times
- Up to 6 different assays in a single run
- Up to 144 results in an 6-hour shift
- Customizable control concept
- Walkaway time of up to 8 hours*
- Compact size: 134cm x 79cm
- Possibility to prioritize samples and assays
* Walkaway time is dependent upon number of runs initiated (under continuous testing conditions >96 tests per shift, walkaway time may be between 4 - 8 hours).
** May vary based on availability in your country.
Run >90% of routine testing on a single platform**
The cobas® 5800 System offers the same assay menu as the cobas® 6800/8800 Systems, including the cobas omni Utility Channel, allowing you to run laboratory-developed tests (LDT) on the same system as in-vitro diagnostic (IVD) assays.
Advanced assay design
Our consistent delivery of breakthroughs in advanced molecular diagnostics displays our commitment to investing in research and development. This investment allows us to stay ahead of constantly evolving diseases. We can also help you make the most appropriate treatment decisions for your patients.
Ensuring confidence in results
The cobas® 5800 System is the all-in-one, automated, compact system with a broader menu and proven assay performance. It provides a hassle-free workflow, ensuring maximum productivity and throughput.
As a member of the Roche family, the cobas® 5800 System has shown equivalent performance compared to the cobas 6800/8800 systems1 and will deliver accurate results in a meaningful and timely manner, which in turn helps clinicians with decision-making and improve patient care.
Deliver high medical value backed by a broad menu and consistent performance
Roche assays are developed according to WHO standards. They deliver consistent quality and collectively set the standard of performance across a broad range of testing needs.
Every Roche assay is backed up by extensive experience and expertise in test design and optimization. Results on Roche instruments are also shown to be standardised and comparable across all platforms.1-5 This consistent excellence has made Roche the preferred diagnostic partner in clinical trials.6-7
The cobas® 5800 System has assays available for donor screening, infectious diseases and respiratory infections, sexual health, and transplant-related infections.
Expanding coverage and extending confidence with advanced approaches to testing
MPLX technology
Proprietary technology that will enable dynamic panel testing, allowing testing of what is medically relevant and necessary.
Dual Target Technology
The rapidly mutating HIV-1 virus can continually evade quantification by a single target viral load assay. Roche's innovative dual target HIV-1 assay measures two unique regions of the HIV-1 genome, which are not subject to selective drug pressure. With this approach, drug-induced mutations should not impact the assay's ability to detect and quantify the virus accurately.
As more accurate results can drive better decisions, we expanded the application of this technology to have a greater impact on patient lives. Incorporating it into our tests for EBV and BKV will help guard against the risk of sequence variations that may be present in the viruses. These tests will work to ensure quantitative accuracy when screening transplant patients at risk of complications caused by the viruses.
Dual Probe Approach
Our quantitative HCV RNA assay is based on a novel dual probe approach with an optimized automated extraction and amplification procedure. This test ensures highly sensitive detection of HCV RNA across different HCV genotypes with accurate and reproducible results at low viral loads. With improved testing, optimized treatment is one step closer—as is putting a stop to the spread of HCV.
See the future of molecular testing
If you would like to learn more about our Molecular solutions or to speak with existing users, please contact your local sales representative, Garry Cusack.
Garry will be happy to demonstrate the system using our 3D web app or meet you at one of our showrooms.
Please complete the form below, and Garry will get back to you asap. Let's continue the conversation.
?wid=402&fmt=png-alpha)
You might be interested in
Frequently Asked Questions
Why Roche?
For well over a century, we’ve focused our energy and investment on developing tests and treatments that change lives and give people more quality time with the people they love.
Each year, we transform millions of lives with our joined-up approach to testing and treatment. But our impact extends far beyond those we treat. Behind every child we test are parents looking for peace of mind; behind every grandparent we treat is a family who can spend more time with them. Roche has supported the nation's health in the UK since 1908, even before the NHS was established. We are a committed, long-term partner to the NHS and the people of this country.
References
- Tschäpe J, Cobernuss-Rahn A, Boyle S, et al. Multisite Performance Evaluation of the cobas 5800 System and Comparison to the cobas 6800/8800 Systems for Quantitative Measurement of HBV, HCV, and HIV-1 Viral Load. Microbiol Spectr. 2022 Dec 21;10(6):e0312522
- Vermehren J, Stelzl E, Maasoumy B, et al. Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. J Clin Microbiol. 2017;55(4):1131-1139.
- Maasoumy B, Bremer B, Lehmann P, et al. Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. Therap Adv Gastroenterol. 2017;10(8):609-618.
- Adams P, Vancutsem E, Nicolaizeau C, et al. Multicenter evaluation of the cobas® HIV-1 quantitative nucleic acid test for use on the cobas® 4800 system for the quantification of HIV-1 plasma viral load. J Clin Virol. 2019;114;43-49.
- Data on file with Roche.
- Data on file with Roche.
- Data on file with Roche.